Loading
A phase 2 trial of Opevesostat, Dexamethasone, Fulvestrant, Exemestane, Megestrol acetate and Tamoxifen in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) is a phase 2 interventional study registered as NCT06979596 by Merck Sharp & Dohme LLC, with 250 participants planned, started 2025-08-11 and due to reach its primary completion in 2027-11-04. Interventions recorded: Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate, Rescue Medications, Fulvestrant and Exemestane.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Exemestane, Fulvestrant, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Tamoxifen, Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Opevesostat, Dexamethasone, Merck & Co. (MSD) and the tag pipeline.
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/